BioLineRx Ltd.
BLRX
$3.22
$0.21797.26%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 144.77% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 144.77% | -- | -- | -- | -- |
| Cost of Revenue | 64.92% | -- | -- | -- | -- |
| Gross Profit | 410.83% | -- | -- | -- | -- |
| SG&A Expenses | -29.43% | -27.90% | 16.43% | 49.42% | 98.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.47% | -16.40% | 12.62% | 31.85% | 98.42% |
| Operating Income | 73.28% | 56.41% | 41.78% | 45.55% | -41.26% |
| Income Before Tax | 77.05% | 63.66% | 102.61% | 94.28% | -142.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 77.05% | 63.66% | 102.61% | 94.28% | -142.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 77.05% | 63.66% | 102.61% | 94.28% | -142.26% |
| EBIT | 73.28% | 56.41% | 41.78% | 45.55% | -41.26% |
| EBITDA | 82.79% | 62.53% | 45.49% | 54.34% | -36.60% |
| EPS Basic | 81.40% | 71.51% | 101.99% | 95.45% | -108.06% |
| Normalized Basic EPS | 78.57% | 72.22% | 102.38% | 95.12% | -7.69% |
| EPS Diluted | 81.40% | 71.51% | 101.99% | 95.45% | -108.06% |
| Normalized Diluted EPS | 78.57% | 72.22% | 102.38% | 95.12% | -7.69% |
| Average Basic Shares Outstanding | 21.30% | 29.11% | 29.75% | 17.73% | 16.66% |
| Average Diluted Shares Outstanding | 21.30% | 29.11% | 29.75% | 17.73% | 16.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |